View More View Less
  • 1 Marosvásárhelyi George Emil Palade Orvosi, Gyógyszerészeti, Tudomány- és Technológiai Egyetem, Marosvásárhely, Románia
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Összefoglaló. Bevezetés: A tudományos szakirodalomban számos kérdés fogalmazódik meg a pajzsmirigybetegségeket befolyásoló pszichológiai tényezőkről. Kevés tanulmány készült a pajzsmirigybetegségek és a megküzdési stratégiák kapcsolatáról. Célkitűzés: Jelen tanulmányunk célja felmérni a megküzdési stratégiák, a depresszió és a szorongás szintjének változásait a pajzsmirigybetegek (hyperthyreosis és hypothyreosis) esetében a gyógyszeres kezelés (Thyrozol és Euthyrox) hatására. Módszer: A betegeket a szakorvos diagnózisa, illetve a TSH- és fT4-szint alapján hyperthyreosis- (n = 10) és hypothyreosis- (n = 21) csoportba soroltuk. Mindkét csoport tagjait az endokrinológiai kezelés előtt és után pszichológiai felmérésnek vetettük alá. A felmérés során a megküzdési stratégiák felméréséhez a következő skálákat alkalmaztuk: Kognitív Érzelem Szabályozás Kérdőív (Cognitive Emotion Regulation Questionnaire – CERQ), Hobfoll-féle Megküzdési Stratégia Kérdőív (Strategic Approach to Coping Scale – SACS). A Beck Depresszió Kérdőívet (Beck Depression Inventory – BDI-II) alkalmaztuk a depresszió felmérésére, az Állapot- és Vonásszorongás Kérdőívet (State-Trait Anxiety Inventory, Form Y – STAI-Y) a szorongás szintjének felmérésére. Eredmények: A két csoport pszichológiai és laboreredményeit összehasonlítottuk a gyógyszeres kezelés előtt és után. Mind a hyperthyreosisban, mind a hypothyreosisban szenvedő betegeknél magas volt a depresszió és a szorongás szintje. A hyperthyreosisban szenvedő betegeknél a depresszió magasabb. A gyógyszeres kezelés után a depresszió és a szorongás szintje csökkent mindkét csoportban, a megküzdési stratégiák többnyire változatlanok maradtak. Következtetések: Pajzsmirigybetegeknél a kognitív viselkedésbeli pszichoterápiás beavatkozás a gyógyszeres kezelés kiegészítő alternatívája lehet a szorongás és a depresszió szintjének csökkentése és a diszfunkcionális megküzdési stratégiák módosítása szempontjából. Orv Hetil. 2021; 162(7): 262–268.

Summary. Introduction: There is a high interest in the scientific literature in psychological factors that influence the course of thyroid disease. There are a few studies on the link between thyroid disease and coping strategies. Objective: In the present study, we aimed to evaluate the manifestation of depression, anxiety and coping strategies in people with thyroid disease and the impact of endocrinological medication on these psychologic items. Method: The patients were grouped into two groups, hyperthyroid (n = 10) and hypothyroid (n = 21), according to the diagnosis established by the attending physician, TSH and fT4 level. Patients with hyperthyroidism and hypothyroidism were evaluated before and after endocrinological treatment with the Cognitive Emotion Regulation Questionnaire (CERQ), Strategic Approach to Coping Scale (SACS) for the evaluation of coping strategies, Beck Depression Inventory (BDI-II) for assessing the level of depression, State-Trait Anxiety Inventory, Form Y (STAI-Y) for assessing anxiety. These two groups have been compared. Results: The psychological and laboratory results of the two groups were compared before and after drug treatment. Both patients with hyperthyroidism and with hypothyroidism had high levels of depression and anxiety. In hyperthyroidism, depression is more severe. Following treatment with Thyrozol and Euthyrox, the level of depression and anxiety decreases in patients with hyper- and hypothyroidism; the coping strategies remained almost unchanged. Conclusion: Cognitive-behavioral psychotherapeutic intervention could be supplementary to drug treatment in terms of reducing anxiety, depression, and modifying dysfunctional coping strategies for patients with thyroid diseases. Orv Hetil. 2021; 162(7): 262–268.

  • 1

    Fukao A, Takamatsu J, Murakami Y, et al. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves’ disease. Clin Endocrinol (Oxf). 2003; 58: 550–555.

  • 2

    Prummel MF, Strieder T, Wiersinga WM. The environment and autoimmune thyroid diseases. Eur J Endocrinol. 2004; 150: 605–618.

  • 3

    Krohne HW. Stress and coping theories. In: Smelser NJ, Baltes PB. (eds.) International encyclopedia of the social and behavioral sciences. Elsevier, Amsterdam, New York, NY, 2001; pp. 15163–15170.

  • 4

    Perțe A, Țincaș I. Handbook for use of the Cognitive Emotion Regulation Questionnaire. Adaptation and standardization of CERQ on the population in Romania. [Manual de utilizare a Chestionarului de coping cognitiv – emoțional. Adaptarea și stanardizarea CERQ pe populația din România.] Editura ASCR, Cluj Napoca, 2009; pp. 468–502. [Romanian]

  • 5

    Cheng C. Cognitive and motivational processes underlying coping flexibility: a dual-process model. J Pers Soc Psychol. 2003; 84: 425–438.

  • 6

    Cheng C, Cheung MW. Cognitive processes underlying coping flexibility: differentiation and integration. J Pers. 2005; 73: 859–886.

  • 7

    Aldao A, Nolen-Hoeksema S, Schweizer S. Emotion-regulation strategies across psychopathology: a meta-analytic review. Clin Psychol Rev. 2010; 30: 217–237.

  • 8

    Kashdan TB, Rottenberg J. Psychological flexibility as a fundamental aspect of health. Clin Psychol Rev. 2010; 30: 865–878.

  • 9

    Sait Gönen M, Kisakol G, Savas Cilli A, et al. Assessment of anxiety in subclinical thyroid disorders. Endocr J. 2004; 51: 311–315.

  • 10

    Trifu S. Mental fragility and psychosomatic illness. Rom J Psychiatry 2011; 13: 37–44.

  • 11

    Bahls SC, de Carvalho GA. The relation between thyroid function and depression: a review. [A relação entre a função tireoidiana e a depressão: uma revisão.] Rev Bras Psiquiatry 2004; 26: 41–49. [Portuguese]

  • 12

    Duntas LH, Maillis A. Hypothyroidism and depression: salient aspects of pathogenesis and management. Minerva Endocrinol. 2013; 38: 365–377.

  • 13

    Hage MP, Azar ST. The link between thyroid function and depression. J Thyroid Res. 2012; 2012: 590648.

  • 14

    Kamble MT, Nandedkar PD, Dharme PV, et al. Thyroid function and mental disorders: an insight into the complex interaction. J Clin Diagn Res. 2013; 7: 11–14.

  • 15

    Yu D, Zhou H, Yang Y, et al. The bidirectional effects of hypothyroidism and hyperthyroidism on anxiety-and depression-like behaviors in rats. Horm Behav. 2015; 69: 106–115.

  • 16

    Conner SH, Solomon SS. Psychiatric manifestations of endocrine disorders. J Hum Endocrinol. 2017; 2: 007.

  • 17

    Larisch R, Kley K, Nikolaus S, et al. Depression and anxiety in different thyroid function states. Horm Metab Res. 2004; 36: 650–653.

  • 18

    Ittermann T, Völzke H, Baumeister SE, et al. Diagnosed thyroid disorders are associated with depression and anxiety. Soc Psychiatry Psychiatr Epidemiol. 2015; 50: 1417–1425.

  • 19

    Suwalska A, Lacka K, Lojko D, et al. Quality of life, depressive symptoms and anxiety in hyperthyroid patients. Rocz Akad Med Bialymst. 2005; 50(Suppl 1): 61–63.

  • 20

    Engum A, Bjøro T, Mykletun A. An association between depression, anxiety and thyroid function – a clinical fact or an artefact? Acta Psychiatr Scand. 2002; 106: 27–34.

  • 21

    Demet MM, Ozmen B, Deveci A, et al. Depression and anxiety in hypothyroidism. West Indian Med J. 2003; 52: 223–227.

  • 22

    Davis JD, Tremont G. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. Minerva Endocrinol. 2007; 32: 49–65.

  • 23

    Constant EL, Adam S, Seron X, et al. Anxiety and depression, attention, and executive functions in hypothyroidism. J Int Neuropsychol Soc. 2005; 11: 535–544.

  • 24

    Gulseren S, Gulseren L, Hekimsoy Z, et al. Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch Med Res. 2006; 37: 133–139.

  • 25

    Samuels MH, Schuff KG, Carlson NE, et al. Health status, mood, and cognition in experimentally induced subclinical thyrotoxicosis. J Clin Endocrinol Metab. 2008; 93: 1730–1736.

  • 26

    Bunevicius R, Prange AJ Jr. Psychiatric manifestations of Graves’ hyperthyroidism: pathophysiology and treatment options. CNS Drugs 2006; 20: 897–909.

  • 27

    Budău O, Albu M. SACS: The scale of the strategic approach to coping. [Scala de abordare strategicã a coping-ului.] Editura ASCR, Cluj Napoca, 2010. [Romanian]

  • 28

    Hobfoll SE, Schroeder KE. Distinguishing between passive and active prosocial coping: bridging inner-city women’s mental health and AIDS risk behavior. J Soc Pers Relat. 2001; 18: 201–217.

  • 29

    Beck AT, Steer RA, Brown GK. Beck Depression Inventory – second edition (BDI-II). [Inventarul de Depresie Beck – editia a doua (BDI-II).] Editura Romanian Psychological Testing Services, Cluj Napoca, 2012; pp. 87–89. [Romanian]

  • 30

    Spielberger CD. State-trait anxiety inventory, form Y. [State-trait anxiety inventory Y form – traducere în limba română.] Editura Test Central, București, 2007. [Romanian]

  • 31

    Sawilowsky SS. New effect size rules of thumb. J Mod Appl Stat Methods 2009; 8: 597–599.

  • 32

    Dryden W, Digiuseppe R. Guide to rational-emotional and behavioral therapy. [Ghid de terapie raţional-emotivă şi comportamentală.] Editura Romanian Psychological Testing Services, Cluj Napoca, 2003. [Romanian]

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Nov 2020 0 0 0
Dec 2020 0 0 0
Jan 2021 0 0 0
Feb 2021 67 24 39
Mar 2021 62 9 11
Apr 2021 52 4 4
May 2021 0 0 0